Canagliflozin (InvokanaÂ®): a First-in-Class Anti-diabetic Drug
AbstractThe US Food and Drug Administration have approved (on March 29, 2013) a novel glucose-lowering agent, canagliflozin (Invokana, Janssen Pharmaceuticals) for the treatment of adults with type 2 diabetes. Canagliflozin isÂ the first in a new class of drug, an oral inhibitor of sodium glucose cotransporter 2 (SGLT2). Inhibition of SGLT2 decreases glucose reabsorption in the renal tubule and increases urinary glucose excretion (UGE), with a consequent lowering of plasma glucose levels as well as weight loss.The profile of effective glucose lowering, weight loss, improved b-cell function, and low risk of hypoglycemia suggest that canagliflozin may be a clinically useful new antihyperglycemic agent.
Download data is not yet available.
61 Views | 41 Downloads
How to Cite
Sen, S. (2013). Canagliflozin (InvokanaÂ®): a First-in-Class Anti-diabetic Drug. Journal of Drug Delivery and Therapeutics, 3(3), 145-146. https://doi.org/10.22270/jddt.v3i3.490
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeÂ The Effect of Open Access).